Douglas Adkins, MD

Medical Oncologist

Douglas Adkins

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108

Expertise & Training

Clinical Expertise

  • Head and Neck Cancer

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Medical Oncology, WashU Medicine

Board Certification

  • 1990: American Board of Internal Medicine, Internal Medicine
  • 1993: American Board of Internal Medicine, Medical Oncology
  • 2000: American Board of Internal Medicine, Internal Medicine
  • 2003: American Board of Internal Medicine, Medical Oncology

Training

  • 1986 - 1989: Intern and Resident, Internal Medicine, University of Texas Health Science Center, San Antonio, TX
  • 1989 - 1990: Fellow, Medical Oncology/Hematology, University of Texas Health Science Center, San Antonio, TX
  • 1990 - 1992: Fellow, Bone Marrow Transplantation, University of Texas Health Science Center, San Antonio, TX

Education

  • 1986: MD, Wright State University, Dayton, OH

Research & Select Publications

Research Interest

Evaluation of targeted therapy approaches in patients with head and neck squamous cell carcinoma and thyroid cancer.

Research Publications

Systemic Treatment of Thyroid Cancer: ASCO Guideline
Authors:

Saba NF, Ismaila N, Adkins D, one or more additional authors omitted Beadle BM

Journal & Year:

J Clin Oncol | 2026

Postoperative Lymph Is a Proximal Source of ctDNA for Detection of Recurrence in HPV-Independent Head and Neck Cancer
Authors:

Lazare S, Gu Z, Earland N, one or more additional authors omitted Adkins D, one or more additional authors omitted Zevallos JP

Journal & Year:

Clin Cancer Res | 2026

Nanoparticle Albumin-Bound Paclitaxel and Nivolumab for PD-1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma
Authors:

Adkins D, Ley JC, Auberle C, one or more additional authors omitted Oppelt P

Journal & Year:

Cancer Med | 2026

Mitomycin-C for HPV-Positive and HPV-Negative Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial
Authors:

Oppelt P, Ley J, Auberle C, one or more additional authors omitted Adkins D

Journal & Year:

Cancers (Basel) | 2025

In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target
Authors:

Fu C, Saddawi-Konefka R, Chinai JM, one or more additional authors omitted Adkins DR, one or more additional authors omitted Manguso RT

Journal & Year:

Nat Commun | 2025

Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Authors:

Uppaluri R, Haddad RI, Tao Y, one or more additional authors omitted Adkins D

Journal & Year:

N Engl J Med | 2025

Neoadjuvant Chemotherapy and Surgery versus Surgery for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma: ECOG-ACRIN EA3163
Authors:

Saba NF, Flamand Y, Lin DT, one or more additional authors omitted Adkins DR, one or more additional authors omitted Burtness BA

Journal & Year:

Clin Cancer Res | 2025

Development and validation of the Immune Profile Score (IPS), a novel multiomic algorithmic assay for stratifying outcomes in a real-world cohort of patients with advanced solid ca…
Authors:

Zander AD, Erbe R, Liu Y, one or more additional authors omitted Adkins D, one or more additional authors omitted Cohen EEW

Journal & Year:

J Immunother Cancer | 2025

Palbociclib, a Selective CDK4/6 Inhibitor, Administered Before and After Chemoradiotherapy for Human Papillomavirus-Negative, Locally Advanced Head and Neck Squamous Cell Carcinoma…
Authors:

Oppelt PJ, Ley JC, Puram SV, one or more additional authors omitted Adkins DR

Journal & Year:

JCO Precis Oncol | 2025

Transoral Robotic Surgery in the Multidisciplinary Care of Patients With Oropharyngeal Squamous Cell Carcinoma: ASCO Guideline
Authors:

Holsinger FC, Ismaila N, Adkins DR, one or more additional authors omitted Ku JA

Journal & Year:

J Clin Oncol | 2025

T cell dynamics with neoadjuvant immunotherapy in head and neck cancer
Authors:

Zhao M, Schoenfeld JD, Egloff AM, one or more additional authors omitted Adkins DR, Uppaluri R

Journal & Year:

Nat Rev Clin Oncol | 2025

NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
Authors:

Colevas AD, Cmelak AJ, Pfister DG, one or more additional authors omitted Adkins D, one or more additional authors omitted Darlow SD

Journal & Year:

J Natl Compr Canc Netw | 2025

Tazemetostat, a Selective EZH2 Inhibitor, in Combination with Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 1 Trial
Authors:

Oppelt PJ, Puram SV, Liu J, Ley JC, Adkins D

Journal & Year:

Cancers (Basel) | 2025

Olaparib, Pembrolizumab, and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase II Trial
Authors:

Adkins D, Ley JC, Liu J, Oppelt P

Journal & Year:

JCO Oncol Adv | 2025

Multicenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the PREDAPT study
Authors:

Flanagan KC, Earls J, Hiken J, one or more additional authors omitted Adkins D, Duncavage EJ

Journal & Year:

J Immunother Cancer | 2024